La semaglutida pertenece a una clase de medicamentos llamados agonistas del receptor GLP-1 , que activan las mismas vas biolgicas que la hormona GLP-1 natural producida en el intestino despus de las comidas
Semaglutida semanal de 2,4 mg (Wegovy, Novo Nordisk), un agonista del receptor de GLP-1, es el primer frmaco aprobado para el control de peso crnico en adultos con obesidad general o sobrepeso desde 2014
This is when the micronutrient support matters most long-term GLP-1 use is associated with progressive nutrient depletion (Urbina 2026), and consistent replenishment is the countermeasure.*
However, long-term safety data are limited because most randomized trials run for a few weeks to several months
Data Availability All data generated or analyzed during this study are included in this published article and its supplementary information files
Am J Kidney Dis 2019;74:682e95